GlobalData : Despite positive efficacy data highlighted at A

18 Apr, 2024 Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic's ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData
...

Related Keywords

United States , American , Pzifer Nurtec Rimegepant , Philippa Salter , Abbvie Ubrelvy , American Academy Of Neurology , Currax Pharmaceuticals Treximet , American Academy , Axsome Therapeutics , Seniorneurology Analyst , Currax Pharmaceuticals , Markets ,